Beactica BEA-17 IND-Enabling Studies for Glioblastoma
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The news is a small-cap, single-company clinical milestone with no immediate revenue or regulatory approval, so its direct market impact is limited and largely confined to sentiment around private biotech and glioblastoma immunotherapy themes. It may modestly support interest in targeted protein degradation and epigenetic oncology platforms, but broader market indices and large-cap pharma are unlikely to move materially.
Bicara Therapeutics AB, a privately held Swedish precision medicine company, announced on September 22, 2026 the initiation of IND-enabling studies for BEA-17, its wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST, being developed as a precision immunotherapy for glioblastoma (GBM). The studies move BEA-17 from preclinical proof-of-concept into the formal safety, manufacturing and regulatory programme needed to support a Clinical Trial Application (CTA) in the European Union and/or an Investigational New Drug (IND) application in the United States, and the start of first-in-human clinical trials. The programme comprises GLP-compliant repeat-dose toxicology in rodent and non-rodent species, safety pharmacology, pharmacokinetic studies, and manufacture of a traceable, fully documented batch of BEA-17 drug substance suitable for a CTA and a finalised oral clinical trial formulation. BEA-17 has been granted Orphan Drug Designation by the United States — Food and Drug Administration for the treatment of glioblastoma. The work is conducted under GLIOBREAK, a 30-month project supported by a EUR 2.5 million EIC Transition grant under Horizon Europe, awarded by the European Union and announced in February 2026. Beactica expects to complete the IND-enabling programme and submit a CTA in the European Union and/or an IND application to the United States — Food and Drug Administration in 2027. Glioblastoma is the most common and most aggressive primary brain tumour, with median overall survival of around 15 months and a standard of care essentially unchanged for more than two decades; immunotherapies have repeatedly failed in GBM because of its immunosuppressive, immune-cold microenvironment. In preclinical models, BEA-17 combined with standard of care substantially improved survival and produced durable tumour regression not seen with standard of care alone.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard